Powered for Precision

Revitope Oncology is revolutionizing immunotherapy to safely and effectively treat more cancers, bringing hope to patients for healthier and longer lives.

A New and Better Way

Revitope is transforming the way immunotherapeutic drugs are designed. As experts in antibody engineering with a deep understanding of the cellular processes underlying immune-based drugs, we are leveraging biological insights and proven protein modules to design “gated” immunotherapies – medicines with sophisticated built-in control mechanisms for precision tumor targeting and controlled immune activation.

Current Challenges with Immunotherapy

First generation immunotherapies have transformed the way cancer is treated, but “on-target, off-tumor” toxicity due to lack of specificity have limited their potential and presented challenges for broad use in patients. There is now an urgent need for new innovative approaches that more precisely target cancer cells and focus immunological responses selectively on the tumor.

A Breadth of Possibilities

We are developing a new class of cancer therapy – drugs derived from proven protein modules, intelligently assembled to selectively target tumor cells and designed to elicit a powerful gated immune response focused entirely on the tumor. Revitope’s approach is modular, allowing the company to build novel therapies from a host of proven protein-based modules including antibodies, cytokines and other immune cell engagers. The company’s first programs are designed to treat todays deadly cancers with greater efficacy and safety.

Our Precision Gating Technology Platform

The Technology Platform incorporates not one, but three unique control mechanisms to specifically target cancer cells and elicit a powerful immune response focused entirely on the tumor – minimizing toxicity risk and widening the therapeutic window of treatment. Our precision-targeted immunotherapies are antibody-based bispecific prodrugs that open opportunities to treat previously inaccessible cancers today.

Step 1: Precision Dual Targeting
Revitope molecules are uniquely designed to bind specific tumor antigen pairs for greater precision. This means that each cancer cell MUST express both antigens in order for the treatment to become activated at the tumor site.
Step 2: Precision Protease Activation
A stabilizing masking domain attached to a half-life extension module ensures drug molecules remain inactive until they reach the tumor site and bind to their corresponding antigens on cancer cells. It is through proteolytic enzymes enriched within the tumor microenvironment, not in healthy tissues, that demasking of the two T-cell activating components occurs, ensuring tumor specificity. Any proteolytically cleaved molecules unbound to tumor cells are rapidly eliminated from the body.
Step 3: Precision Pairing, T-Cell Activation
Engineered with a split immune cell engaging binding domain (the half-paratope), our molecules behave as inactive prodrugs until both complementary halves bind simultaneously to their individual targets on the same tumor cell. The two complementary T-cell engaging domains can then dimerize and interact with T-cells – resulting in focused immune activation and a powerful therapeutic action directed specifically against the tumor.
Revitope’s first programs are antibody-derived therapies designed to treat difficult cancers. Our lead candidate drug is designed to bind two antigens co-expressed on colorectal and other tumor types, which have been notoriously difficult to target with traditional immunotherapy approaches, largely due to toxicity. Beyond this, Revitope is continuing to build its internal pipeline through the delivery of additional immunotherapies for a range of solid and hematological cancers which today lack effective and safe treatments.
Our Pipeline

Using our Precision Gating Technology Platform, we are building a pipeline of novel cancer immunotherapies designed to elicit a focused and powerful immune response to eradicate tumor cells while leaving healthy tissue unharmed.

Our Team

Revitope is led by a team of creative, highly engaged scientists and industry veterans who have deep experience in protein engineering and immunotherapy with a proven track record of delivering effective biologic therapies that treat cancer and other serious immunological diseases.

Steve Arkinstall Chief Executive Officer, Director
Werner Meier Chief Scientific Officer
Patricia Giblin Vice President of Biology
Ken Simon Head of Protein Sciences
Mark Clement Chief Financial Officer, Chief Business Officer
Lee Ann Marchionna Head of Human Resources
Andrew Allen Executive Chairman
Peter Joost Director
Carsten Reinhardt Director
Raj Mehta Director
Werner Meier Chief Scientific Officer, Director
Steve Arkinstall Chief Executive Officer, Director
News & Media
Revitope Oncology Adds Carsten Reinhardt, a Pioneer of Modern Immunotherapy, to its Board of Directors
CAMBRIDGE, Mass., September 16, 2020 — Revitope Oncology, Inc., a biotechnology company advancing a new class of precision cancer immunotherapies today announced the appointment of life sciences industry veteran Carsten Reinhardt, M.D., Ph.D., to its Board of Director Read More >
Revitope and Junshi Biosciences Enter into Research Collaboration and License Agreement to Explore Next Generation Immunotherapies with Precision-Targeted T-cell Engaging Antibodies
Cambridge, MA & Shanghai, China | July 13, 2020 | Revitope Oncology Inc (“Revitope Oncology”)., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, “Revitope”) and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation‐driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a strategic research collaboration. Read More >
Revitope Oncology Appoints Steve Arkinstall, D.Phil., Chief Executive Officer
Revitope Oncology, Inc., a cancer therapeutics company advancing a novel class of tumor-specific bispecific antibody therapies, today announced the appointment of Steve Arkinstall, D.Phil., as Chief Executive Officer. Read More >
View all
Revitope Oncology Adds Carsten Reinhardt, a Pioneer of Modern Immunotherapy, to its Board of Directors

CAMBRIDGE, Mass., September 16, 2020 — Revitope Oncology, Inc., a biotechnology company advancing a new class of precision cancer immunotherapies today announced the appointment of life sciences industry veteran Carsten Reinhardt, M.D., Ph.D., to its Board of Directors. Dr. Reinhardt is Managing Director and Chief Development Officer of Immatics Biotechnologies and one of the early pioneers of bispecific T cell therapy.

“I am honored to welcome Dr. Reinhardt to the Revitope Board. Carsten is an accomplished and highly regarded leader in immunotherapy with deep knowledge in tumor target identification and extensive experience bringing biological drugs into the clinic,” said Steve Arkinstall, Ph.D., Chief Executive Officer, Revitope Oncology. “We are thrilled to have his insight and wisdom on the Board as we advance our first-in-class precision cancer immunotherapies to the clinic and explore partnership opportunities to expand the reach of our novel therapeutics.”

“Carsten has held impressive leadership roles at several globally respected biopharmaceutical companies that have each had a major impact on the world of bi-specifics and T cell therapies. He is ideally suited to help advance Revitope’s strategic plan and vision,” said Andrew Allen, M.D., Ph.D., Executive Chairman and Founder, Revitope Oncology.

Dr. Reinhardt is a physician scientist who since 2010 has served as Managing Director and Chief Medical Officer and more recently as Chief Development Officer of Immatics, a German/U.S. company that has pioneered the field of tumor antigen identification (HLA-peptide complexes) and is now primarily focused on T cell therapy against these targets. While at Immatics, he has been intimately involved in successful fundraising including becoming public at NASDAQ as well as forging biopharmaceutical partnerships with Bristol Myers Squibb, GSK, Amgen, Roche and others. Prior to joining Immatics, he was Senior Vice President and Chief Medical Officer of Micromet, another pioneering German/U.S. company that drove the field of T-cell engager immunotherapies leading to the first ever FDA regulatory approval of a bispecific antibody (Blincyto™) and its acquisition in 2012 by Amgen for $1.6B. Dr. Reinhardt medicine at Ludwig-Maximilians University in Munich earning a Ph.D. at the Institute of Immunology in Munich in 1994. He has consulted to a variety of biopharma companies and is a visiting professor at the University of Basel in Pharmaceutical Medicine.

“Revitope has developed an incredibly thoughtful protein engineering approach with a platform that overcomes the inherent limitations and challenges of conventional immunotherapies,” said Dr. Reinhardt. “Despite the early success with some hematological cancers, finding specific surface targets for the treatment of solid cancers has been difficult and has hampered the successful translation of bispecific antibodies to the clinic. I strongly believe that the groundbreaking technology Revitope is developing has the potential to finally unlock the benefit of this treatment modality for patients with solid cancers who still desperately need efficacious treatment options.”

About Revitope Oncology, Inc.

Revitope Oncology, Inc. is a privately funded cancer therapeutics company with a focus on innovative tumor-specific antibody based biotherapeutics. Based in Cambridge, MA, the company has conceived, engineered, patented and pre-clinically tested novel classes of bispecific antibody therapeutics designed to enable tumor-specific immunotherapy with improved therapeutic efficacy and safety. For more information, please visit revitope.com or contact us at info@revitope.com.

Media Contact:

Marites Coulter

Verge Scientific Communications

mcoulter@vergescientific.com

+1 415.819.2214

< Back to listing
Revitope and Junshi Biosciences Enter into Research Collaboration and License Agreement to Explore Next Generation Immunotherapies with Precision-Targeted T-cell Engaging Antibodies
  • Novel antibody-based cancer immunotherapies to be developed through combining Revitope’s dual-antigen precision T-cell engager platform (TEAC) and Junshi Biosciences’ antibodies
  • Revitope to design up to 5 TEAC molecules against tumor targets selected by Junshi Biosciences
  • For each TEAC molecule selected, Revitope to receive up to $160M in development and commercialization milestones, plus tiered royalties on net sales
  • Junshi commits to making a conditional equity investment of $10M for 9.99% of Revitope Oncology shares on an as-converted basis

Cambridge, MA & Shanghai, China | July 13, 2020 | Revitope Oncology Inc (“Revitope Oncology”)., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, “Revitope”) and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation‐driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a strategic research collaboration. Revitope will leverage its proprietary protein engineering platform together with Junshi’s novel antibody components to develop first-in-class dual-antigen targeting cancer therapies. Revitope is granting Junshi a world-wide exclusive license on products arising from the research collaboration and will receive up to $160 million in development and commercialization milestone payments for each T Cell Engaging Antibody Circuit (TEAC) molecule selected by Junshi, plus tired royalties. Junshi also commits to making a direct equity investment in Revitope Oncology in the amount of $10M for 9.99% of total Revitope Oncology shares on an as-converted basis with terms and conditions to be mutually agreed and subject to compliance with all applicable laws.

“By leveraging Revitope’s unique two component T-cell immunotherapy platform and our in-house antibody capabilities reaching from discovery to commercialization, dual targeting precision-based novel cancer immunotherapies can be brought into clinical trials in the near future,” commented Dr. Sheng YAO, Vice President of Junshi Biosciences. “As an innovation-driven company, we believe the collaboration with Revitope will empower us to generate a new generation of first-in-class immunotherapy compounds designed to improve both safety and clinical efficacy.”

Revitope’s proprietary T Cell Engaging Antibody Circuit (TEAC) technology platform exploits co-expressed tumor antigens to enable the development of highly specific cancer drugs with improved safety and efficacy over conventional immunotherapeutic approaches. Revitope’s unique approach is based on a pair of tumor-targeted antibodies with a shared T-cell engaging domain which act as inactive pro-drugs unless they encounter cancer cells co-expressing both antigens.

“We are excited to partner with Junshi, a company with state-of-the-art antibody discovery technologies and world-class development capabilities, to advance our unique two-component T-cell engager therapies that have the ability to target tumor cells and deliver more efficacious and safer drugs to patients,” said Steve Arkinstall, PhD, CEO, Revitope Oncology.

Under the terms of the Collaboration and License Agreement, Junshi and Revitope will identify development candidate TEAC pairs against agreed upon targets. Revitope will leverage its TEAC protein engineering platform to develop up to five novel TEAC pairs using proprietary sequences from Junshi’s antibodies with best-in-class pharmacological and therapeutic activity. Junshi will receive a world-wide license to the TEAC pairs and will have sole responsibility for IND enabling studies as well as clinical development, manufacturing and commercialization. Revitope will receive up to $160M in clinical development and commercialization milestone payments for each TEAC molecule selected, plus tiered royalties on net sales.

About Revitope’s T-Cell Engaging Antibody Circuit Technology (TEAC): Tumor-specific Immunotherapies

Because tumors typically do not express cell surface proteins unique to the tumor, conventional bispecific antibody therapeutics can generate unwanted and substantial “on-target, off-tumor” toxicity. Revitope’s two-component T-cell engaging antibody circuits (TEACs) are designed to permit specific recruitment and activation of T-cells exclusively by tumor cells. Though developed with traditional tumor targeting domains, TEAC therapies split the CD3 paratope (the T-cell recognition domain) into two halves, with one half on one molecule and the other half on the other molecule. This allows for true dual-antigen targeting to a unique tumor-specific address – two inputs coming together to enable one precision targeted output i.e. a true “and” gate safety feature. Only when the two molecules come together through binding to their different tumor targets on the same tumor cell can the two halves of the CD3 binding domain recombine and create a fully functional anti-CD3 domain (a TEAC). Normal cells expressing only one or neither of the targeted antigens will not elicit activation of a TEAC pair thereby avoiding unwanted toxicity in healthy tissues.

< Back to listing
Revitope Oncology Appoints Steve Arkinstall, D.Phil., Chief Executive Officer

Cambridge, MA. | January 8, 2020 | PRNewswire | Revitope Oncology, Inc., a cancer therapeutics company advancing a novel class of tumor-specific bispecific antibody therapies, today announced the appointment of Steve Arkinstall, D.Phil., as Chief Executive Officer. Dr. Arkinstall brings more than 30 years of experience in biopharmaceutical research and development across multiple diseases areas, and is a respected industry leader.

Most recently, Dr. Arkinstall was CEO of Elstar Therapeutics, a venture-backed biotechnology company developing multi-functional antibody-based therapeutics to treat cancer. He previously was Chief Scientific Officer at Kymab, an antibody therapeutics company founded in Cambridge, UK, prior to which he spent 16 years in progressively senior research leadership roles at EMD Serono, and associated entities in Europe and the United States.

“We are thrilled that a leader of Steve’s caliber has chosen to join Revitope at this exciting time in the company’s evolution,” said Andrew Allen, M.D., Ph.D., Chair of the Revitope Oncology Board of Directors. “Under the skilled direction of CSO and acting-CEO Werner Meier, the company has advanced its core T-cell engaging antibody circuit (TEAC) technology to successful in vivo studies. We must now select our first development candidates and advance into IND enabling studies as a prelude to clinical trials. Steve is a superlative, and experienced executive ideally equipped to lead us through these critical phases.”

Revitope’s TEAC technology consists of tumor-specific antibody circuits designed to focus immune activation to the cancer cell surface while expanding the antigenic targeting space on solid tumors, avoiding healthy tissues and widening the therapeutic index in immune-oncology.

“A key challenge for immunotherapy for solid tumors in particular, has been the absence of antibody-accessible antigens on the surface of tumor cells which are suitably specific to the tumor,” said Dr. Arkinstall. “Revitope’s “AND” gate technology, applied to antibody therapeutics, is an elegant and unique approach to the problem that offers a powerful solution. I am excited to be joining the team and look forward to driving this therapeutic approach forward to help cancer patients in a compelling new way. There is an abundance of targets to choose from and tremendous opportunity to leverage our technology through both in-house and partnered programs across cancer types.”

< Back to listing
Applied BioMath, LLC Announces Collaboration with Revitope for Mechanistic PK/PD Modeling in Solid Tumors

Concord, MA | July 10, 2018 | PRNewswire—Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk and accelerate drug research and development, today announced a collaboration with Revitope for an in-vitro and human mechanistic PK/PD modeling of Revitope’s bispecific T Cell Engaging Antibody Circuits (TEAC) targeting solid tumors. “TEAC are designed to increase tumor specificity and launch an immune activation only when bound to the cancer cell surface. This innovative engineering approach has the potential to unleash potent immune responses that are focused entirely on the tumor,” said Werner Meier, CSO and acting CEO of Revitope Oncology. “Our goal in this collaboration is to leverage Applied BioMath’s modeling and analyses capabilities to identify TEAC drug properties that drive the potential for a better therapeutic index and ideally more efficacy in immuno-oncology.”

Applied BioMath employs a rigorous fit-for-purpose model development process, referred to as Model-Aided Drug Invention (MADI), which aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their MADI approach employs proprietary algorithms and software that were designed specifically for mechanistic PK/PD modeling. “Our mechanistic modeling approach allows our collaborators to assess the feasibility of their therapeutic much more quickly than if they were to rely on experiments alone,” said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. “They’ll be able to quickly answer strategic questions about the ideal properties for their therapeutic concept and help accelerate development in Lead Generation and by prioritizing experiments, thus helping them get into the clinical faster and for less money with potentially a BIC therapeutic, giving themselves a much higher chance of clinical success and maximizing R&D ROI.”

< Back to listing
Servier backs American startup’s research project at LabCentral

Paris, France & Cambridge, US | April 26, 2018 | GLOBE NEWSWIRE—Independent international pharmaceutical company Servier and LabCentral, a well-known launchpad for innovative startups in the United States, have announced that Revitope, a startup specializing in biotechnology, has won the Golden Ticket awarded by Servier as part of its sponsorship of the prestigious American coworking facility. The prize is a year’s residency at LabCentral’s facilities for a Revitope scientist. Located in Cambridge, LabCentral is at the heart of scientific and technological innovation in the United States.

Servier has been a Gold sponsor of LabCentral for two years. Each year, it can award a Golden Ticket to a startup in the field of healthcare in order to provide support for a research project corresponding to the Group’s development strategy.

“Servier is happy to have given this award to Revitope whose innovative technology could enable the therapeutic antibodies developed by the Group to precisely target the cells to be treated in patients with cancer and inflammatory diseases”, said Olivier Nosjean, Scientific Director of the Center of Excellence Research and Biopharmacy. “In an open-innovation approach, Servier is committed to supporting promising startups in the field of healthcare, and particularly oncology, one of the company’s priority areas of research.”

The Golden Ticket award underwrites the cost of a lab bench for a Revitope scientist to reside in LabCentral’s open lab for one year. This includes access to all the latest research equipment, shared infrastructure, extensive programming and services offered by LabCentral. The start-up will also benefit from LabCentral’s corporate development support (co-working area, business coaching, investor relations).

“A core principle in every aspect of what we do at LabCentral — from the design of our facilities and speaker series to our sponsorship programs and networking events — is a deliberate attempt to encourage interaction and collaboration,” said LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D. “The Golden Ticket program is a great example. It’s enormously gratifying to see our mission come to fruition, with Servier helping to support Revitope’s continued work at LabCentral.”

Revitope Oncology is developing prodrug platforms that have the potential to unleash potent immune responses that are focused entirely on the tumor. The company’s programmable antibody circuits are designed to focus immune activation to the cancer cell surface while expanding the antigenic targeting space on solid tumors to widen the therapeutic index in immune-oncology.

Revitope Chief Scientific Officer Werner Meier, commented, “We are very excited to have been selected by Servier as their Golden Ticket winner for 2017. It is particularly gratifying that an international pharma leader like Servier — laser-focused on bringing innovative therapies to patients across important therapeutic areas including cancer — is recognizing the potential of the Revitope prodrug platforms to widen the therapeutic index for T-cell redirection. The Servier Golden Ticket provides much-appreciated support that helps us to continue to be part of the LabCentral entrepreneur community — a terrific place for young, life sciences companies to grow.”

The cooperation agreement with LabCentral is part of Servier’s dynamic collaborative partnership strategy which aims to better respond to the challenges of therapeutic innovation by placing its research activities in the most dynamic research ecosystems where creativity, innovation and entrepreneurship are promoted and valued. This new agreement also confirms Servier’s commitment to developing its partnership strategy in the United States

< Back to listing
Careers

At Revitope, we are driven by our vision to deliver safer life changing medicines, restoring hope for a healthy future beyond cancer. We value the power of difference and those who bring all of themselves to their work. We embrace cultural, cognitive, social and professional diversity because we know the only way we’re going to make new cures possible is by working together. If that excites you, check out our job openings and see if there’s a match.

Contact Us

For general inquires please e-mail info@revitope.com.